Excuse the poor formatting - below is the list of AZ oncology drugs I found on their website.
I do wonder if the primary strategy is to radically improve the side effects profile of one of these, or to extend the marketability of one?
Also I wonder if this could be an accelerated process with an existing drug being "enhanced". This really should be on the radar for every suitable molecular oncology drug at all major pharma companies?
Inking of deals at ASCO 2019, page-10
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
